<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Pain Res Manag</journal-id><journal-id journal-id-type="iso-abbrev">Pain Res Manag</journal-id><journal-id journal-id-type="pmc-domain-id">531</journal-id><journal-id journal-id-type="pmc-domain">painresmgmt</journal-id><journal-id journal-id-type="publisher-id">PRM</journal-id><journal-title-group><journal-title>Pain Research &amp; Management</journal-title></journal-title-group><issn pub-type="ppub">1203-6765</issn><issn pub-type="epub">1918-1523</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6854236</article-id><article-id pub-id-type="pmcid-ver">PMC6854236.1</article-id><article-id pub-id-type="pmcaid">6854236</article-id><article-id pub-id-type="pmcaiid">6854236</article-id><article-id pub-id-type="pmid">31772694</article-id><article-id pub-id-type="doi">10.1155/2019/3865924</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Opioid Safety and Concomitant Benzodiazepine Use in End-Stage Renal Disease Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ruchi</surname><given-names initials="R">Rupam</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bozorgmehri</surname><given-names initials="S">Shahab</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ozrazgat-Baslanti</surname><given-names initials="T">Tezcan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Segal</surname><given-names initials="MS">Mark S</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shukla</surname><given-names initials="AM">Ashutosh M</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mohandas</surname><given-names initials="R">Rajesh</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4187-0435</contrib-id><name name-style="western"><surname>Kumar</surname><given-names initials="S">Sanjeev</given-names></name><email>skumar@anest.ufl.edu</email><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Division of Nephrology, Department of Medicine, University of Florida, Gainesville, FL, USA</aff><aff id="I2">
<sup>2</sup>Division of Nephrology, Department of Medicine, NF/SG Veteran Healthcare System, University of Florida, Gainesville, FL, USA</aff><aff id="I3">
<sup>3</sup>Division of Pain Medicine, Department of Anesthesiology, University of Florida, Gainesville, FL, USA</aff><author-notes><fn fn-type="other"><p>Academic Editor: Anna Maria Aloisi</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2019</year></pub-date><volume>2019</volume><issue-id pub-id-type="pmc-issue-id">327674</issue-id><elocation-id>3865924</elocation-id><history><date date-type="received"><day>30</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>10</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>26</day><month>11</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-11-29 00:17:38.403"><day>29</day><month>11</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2019 Rupam Ruchi et al.</copyright-statement><copyright-year>2019</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRM2019-3865924.pdf"/><abstract><sec><title>Background</title><p> Opioid use is common in end-stage renal disease (ESRD) patients. However, safety of individual opioids and concomitant benzodiazepine use has not been studied. </p></sec><sec><title>Objective</title><p> To study the epidemiology of opioid and concomitant benzodiazepine use in ESRD population. To study the clinical safety profile of individual opioids in patients on hemodialysis. </p></sec><sec><title>Design</title><p> Retrospective analysis of the U.S. Renal Data System. A comprehensive review of the current literature was performed to update currently used opioid safety classification. </p></sec><sec><title>Participants</title><p> ESRD patients &#8805;18 years on hemodialysis who were enrolled in Medicare A and B and Part D between 2006 and 2012, excluding those with malignancy. </p></sec><sec><title>Main Measures</title><p> Hospital admission with diagnosis of prescription opioid overdose within 30, 60, and 90 days of prescription; death due to opioid overdose. </p></sec><sec><title>Results</title><p> Annually, the percentage of patients prescribed any opioid was 52.2%. Overall trend has been increasing except for a small dip in 2011, despite which the admissions due to opioid overdose have been rising. 30% of those who got a prescription for opioids also got a benzodiazepine prescription. 56.5% of these patients received both prescriptions within a week of each other. Benzodiazepine use increased the odds of being on opioids by 3.27 (CI 3.21&#8211;3.32) and increased the odds of hospitalization by 50%. Opioids considered safe such as fentanyl and methadone were associated with 3 and 6 folds higher odds of hospitalization within 30 days of prescription. Hydrocodone had the lowest odds ratio (1.9, CI 1.8&#8211;2.0). </p></sec><sec><title>Conclusions</title><p> Concurrent benzodiazepine use is common and associated with higher risk of hospitalization due to opioid overdose. Possible opioid-associated hospital admission rate is 4-5 times bigger in ESRD population than general population. Current safety classification of opioids in these patients is misleading, and even drugs considered safe based on pharmacokinetic data are associated with moderate to very high risk of hospitalization. We propose a risk-stratified classification of opioids and suggest starting to use them in all ESRD patients.</p></sec></abstract><funding-group><award-group><funding-source>University of Florida</funding-source><award-id>R01 GM110240</award-id><award-id>P50 GM-111152</award-id><award-id>97071</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Pain is a distressing symptom in patients with end-stage renal disease (ESRD), affecting over 50% of population [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B4" ref-type="bibr">4</xref>]. It has a negative impact on multiple patient outcomes such as quality of life, depression, and adherence to dialysis [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>] that are strongly associated with higher morbidity and mortality [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>Management of pain in ESRD population is difficult and suboptimal. The modified WHO ladder for pain management in ESRD proposes opioids for moderate-to-severe pain, defined as rating of 5 and above on the visual analog scale [<xref rid="B8" ref-type="bibr">8</xref>]. These protocols have been shown to have excellent efficacy for analgesia in about 96% of ESRD patients over 4 weeks but with real potential for opioid misuse and diversion of the prescription, which can further lead to overdose and related complications. Thus, a dichotomous reality exists for the management of pain among patients with ESRD. On one hand, pain is under-managed in this population [<xref rid="B9" ref-type="bibr">9</xref>], while on the other hand, injudicious use of opioids either alone or in combination with additional narcotics results in accumulation of the opioid and/or their active metabolites resulting in higher adverse effects and mortality.</p><p>The 2012 American Academy of Family Physicians guidelines for opioid use [<xref rid="B10" ref-type="bibr">10</xref>] categorically classifies opioids as &#8220;safe,&#8221; &#8220;unsafe,&#8221; or &#8220;to be used with caution.&#8221; However, these guidelines are based on older reports [<xref rid="B11" ref-type="bibr">11</xref>], and there is a lack of guidance for many of the modern opioid analgesics. Further, the categorical classification is largely derived from small pharmacokinetic studies done on dialysis patients or case reports, and it lacks the safety demonstrations for their long-term clinical use. Finally, these guidelines do not provide any guidance regarding the concomitant use of benzodiazepines, which could be a marker for substance use, and known risk factors for increased hospitalizations and mortality in general population. However, benzodiazepines could also have legitimate medical use for appropriate symptom control in a chronically ill patient population, and not every prescription should be viewed in the context of a substance use problem in ESRD patients. Little is known about the concurrent opioids and benzodiazepine use and safety in ESRD population.</p><p>The overall aim of this study is to characterize the use of opioids alone and in combination with benzodiazepines in ESRD population and to correlate it with their safety outcomes to further assist determination of the pragmatic safety of these drugs in clinical practice.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Study Design, Date Sources, and Patient Selection</title><p>We conducted a retrospective study of U.S. Renal Data System (USRDS) database (2014) using the standard analysis files. Using USRDS core dataset, we included ESRD patients with complete identifiers and consistent dates (i.e., annual data reports, ADR&#8201;=&#8201;1). We used treatment history dataset to identify and include ESRD patients &#8805;18 years of age on hemodialysis who were enrolled in Medicare with Part D coverage between 2006 and 2012. We used ESRD Medicare prescription drug enrollment dataset to obtain information on whether patients were enrolled in Part D in each corresponding year. The demographics and etiology of kidney disease were obtained using core dataset and data on comorbid conditions including diabetes, hypertension, peripheral vascular disease, stroke, and coronary artery disease, and history of smoking, alcohol, and substance abuse was obtained using Centers for Medicare and Medicaid Services (CMS) Medical Evidence Report (CMS-2728). We excluded patients on peritoneal dialysis (PD) and patients with malignancy. The selection of patients is presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></sec><sec id="sec2.2"><title>2.2. Opioid Prescriptions</title><p>We used ESRD Medicare Prescription Drug Events dataset to obtain information on prescription opioids or benzodiazepines. Only oral and transdermal formulations (e.g., fentanyl patch) of opioids were considered. We considered patients with opioid prescription use if they had at least one opioid prescription throughout the study period. We also examined if a patient had at least an opioid prescription in each of the corresponding year that they were enrolled in Medicare Part D.</p></sec><sec id="sec2.3"><title>2.3. Opioid Classification</title><p>The available classification of opioids released in 2012 by the American Academy of Family Physicians [<xref rid="B10" ref-type="bibr">10</xref>] for ESRD population classifies them as those that are &#8220;safe to use&#8221; or &#8220;unsafe to use.&#8221; Opioids with limited data for safety profile are classified as &#8220;use with caution.&#8221; This classification was based on older data based on pharmacokinetics [<xref rid="B11" ref-type="bibr">11</xref>]. We have used this classification as baseline; however, we have modified this to incorporate the newer safety evidence for the existing opioids and to add the newer medications. In order to do this in the most evidence-based possible way, we formed a 2-member expert committee (Kumar specializing in pain medicine and Ruchi specializing in nephrology), both of whom independently reviewed the available literature to update the classification. A detailed updated classification and methodology is referenced in the supplement [<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>] (<xref ref-type="supplementary-material" rid="supplementary-material-1"/>).</p></sec><sec id="sec2.4"><title>2.4. Adverse Events</title><p>We used hospitalization dataset to identify hospital admission with a diagnosis of prescription opioid overdose using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) codes. We used the following ICD-9 CM codes: 965.00, 965.02, 965.09, E850.1, and E850.2 for prescription opioid overdose. We also looked at hospital admissions due to prescription opioid overdose within 30, 60, and 90 days of an opioid prescription. The limitation of this method was that the codes for opioid overdose did not indicate if the overdose happened due to intentional self-harm, accidental overdose, or due to deteriorating renal function without adjustment of opioid dosage (there could be several reasons for opioid overdose, which cannot be ascertained by this methodology). We then compared this data with the pharmacokinetic safety class of the individual opioids to see if they corroborate. For this purpose, we categorized the drugs as those associated with mild (OR 1.01&#8211;1.9), moderate (OR 2&#8211;2.9), high (OR 3&#8211;3.9), and very high (OR &gt;4) odds of hospitalization due to opioid overdose. Drugs with OR &lt;1 were considered safe.</p><p>For the purpose of this study, we defined death due to opioid overdose as any death due to drug overdose that occurred during a hospitalization with a diagnosis of prescription opioid overdose. We calculated the total length of stay and ICU length of stay using hospitalization dataset. We calculated annual Medicare cost per patient using institutional claims dataset.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>Baseline demographics and clinical characteristics were compared between patients with and without opioid prescriptions using one-way analysis of variance (ANOVA) and chi-square tests for continuous and categorical variables, respectively. The annual trend in the proportions of patients with at least one opioid prescription was examined using Cochran&#8211;Armitage test for trend. The difference between frequencies and distributions of adverse events due to opioid prescriptions between patients with and without opioid prescriptions were examined using Wilcoxon&#8211;Mann&#8211;Whitney test for nonnormally distributed continuous variables and chi-square test for categorical variables. The association between patient factors and having at least one opioid prescription were examined using univariate and multivariable logistic regression models. The association between hospital admission with a diagnosis of opioid overdose and odds of opioid prescription drugs within 30, 60, and 90 days was analyzed using univariate and multivariable logistic regression models, which included all opioids and benzodiazepine use odds ratio (OR) and 95% confidence interval (CI), and <italic toggle="yes">p</italic> values were reported. All significance tests were two-sided, with a <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 considered statistically significant. Statistical analyses were performed using Statistical Analysis Software (SAS) version 9.4 (SAS Institute Inc., Cary, North Carolina).</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Study Cohort and Patient Characteristics</title><p>Out of 643,859 patients included in the final cohort, 480,460 (74.6%) patients received at least one prescription of opioid throughout the study period (<xref ref-type="fig" rid="fig1">Figure 1</xref>). A total of 6,665,906 opioid prescriptions were written with an average of 13.8 prescriptions per patient. When categorized by annual prescriptions, 52.2% of all patients received at least one opioid prescription. In all, opioids comprised 5.6% of all prescriptions written for these patients. The clinical characteristics of patients with and without opioid prescriptions are presented in <xref rid="tab1" ref-type="table">Table 1</xref>. The association between clinical characteristics and having an opioid prescription is presented in <xref rid="tab2" ref-type="table">Table 2</xref>.</p></sec><sec id="sec3.2"><title>3.2. Trends in Opioid Prescription from 2006 to 2012</title><p>Opioid-prescribing rate (OPR), described by CDC as number of prescriptions per 100 persons per year, was 306 in 2012. Over the study period, the OPR increased from 267 in 2006 to 306 in 2012 (<italic toggle="yes">p</italic> &lt; 0.001). <xref ref-type="fig" rid="fig2"> Figure 2(a)</xref> shows a significantly rising trend (<italic toggle="yes">p</italic> &lt; 0.001) towards progressively increasing frequency of opioid use both in terms of number of patients getting opioids as well as the total number of opioid prescriptions written.</p></sec><sec id="sec3.3"><title>3.3. Safety of Prescribing Patterns</title><p>Over the study period, only 8.52% of the opioids prescribed were in the &#8220;safe&#8221; category, whereas 81.6% of these were in the &#8220;use with caution&#8221; category and 9.88% were in the &#8220;unsafe&#8221; category. Overall, there was a trend for decreased use of &#8220;unsafe opioids&#8221; and greater use of &#8220;use with caution&#8221; opioids during the study period (<italic toggle="yes">p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>).</p></sec><sec id="sec3.4"><title>3.4. Adverse Events in Patients Who Received Opioid Prescriptions</title><p>Among patients with at least one opioid prescription, 3,231 patients had 4,014 hospital admissions with opioid overdose, with 5 deaths. The median length of hospital and ICU stay due to opioid overdose was 4 (IQR: 2&#8211;8) and 2 (IQR 1&#8211;4) days, respectively. The annual Medicare cost per patient in this group was $46,000 as compared to $33,000 in those without opioid prescription, <italic toggle="yes">p</italic> &lt; 0.001 (<xref rid="tab3" ref-type="table">Table 3</xref>). In 2006, 10/10,000 hospital admissions were attributed to opioid overdose. This number increased to 13, 15, and 16 per 10,000 hospitalizations in 2010, 2011, and 2012, respectively (<italic toggle="yes">p</italic> trend&#8201;&lt;&#8201;0.001), <xref ref-type="fig" rid="fig2">Figure 2(a)</xref>.</p></sec><sec id="sec3.5"><title>3.5. Association between Opioid Class and Hospitalization from Opioid Overdose</title><p>The adjusted odds ratio for hospitalization with prescription opioid overdose within 30, 60, and 90 days of prescription is shown in <xref rid="tab4" ref-type="table">Table 4</xref>. Based on the OR at 30 days, opioids were reclassified into low, moderate, high, and very high risk drugs.</p><p>Among the safe category of drugs, fentanyl and hydromorphone were associated with 2.5&#8211;3 times higher odds of hospitalization. Methadone was found to be associated with a very high risk of hospitalization at 30 days (OR 5.9) that persisted at 60 and 90 days (OR 5.3 and 4.7, respectively).</p><p>Among the unsafe drugs, morphine and meperidine were associated with very high risk of hospitalization. The odds ratio of propoxyphene, tapentadol, and codeine was not significant likely because they accounted for only 0.11%, 0.06%, and 0.02% of all prescriptions (<xref ref-type="supplementary-material" rid="supplementary-material-1"/>).</p><p>Among the drugs to be used with caution, hydrocodone had the lowest odds ratio for admission. Oxycodone demonstrated a high risk of hospitalization due to opioid overdose, similar to fentanyl; oxymorphone also resulted in a very high risk of hospitalization. Buprenorphine was associated with a very high risk of hospitalization within 30 days (OR 5.4) that persisted at 90 days.</p></sec><sec id="sec3.6"><title>3.6. Concomitant Prescription of Opioid and Benzodiazepines</title><p>The largest difference between the two groups (opioid use and nonuse) was found to exist in the use of benzodiazepine, which occurred at 30% in the opioid population compared to 11% in the nonopioid population (<italic toggle="yes">p</italic> &lt; 0.001). 56.5% of individuals who received both a benzodiazepine and opioid prescription, received them within a week of each other. Patients in the opioid group were three times more likely to be on benzodiazepines (adjusted OR 3.271, 95% CI: 3.216&#8211;3.326) (<xref rid="tab2" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3.7"><title>3.7. Association between Benzodiazepine Prescription and Hospitalization from Opioid Overdose</title><p>Having a prescription of benzodiazepines significantly increased the odds of hospitalization due to opioid overdose by 50% within 30, 60, and 90 days (<italic toggle="yes">p</italic> value for all&#8201;&lt;&#8201;0.05). Benzodiazepine use prior to hospitalization was significantly higher in patients who were admitted for opioid overdose compared to those who were admitted without this diagnosis (40% vs. 24%, respectively, <italic toggle="yes">p</italic> &lt; 0.001; OR 2.37; CI 2.21&#8211;2.54). There was no significant difference in mortality.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The CDC data on the general population demonstrates that, in 2016, 19.1% of adults received a prescription for opioid, with an OPR of 66 [<xref rid="B37" ref-type="bibr">37</xref>]. Based on these statistics, opioid (ab)use is considered a major public health problem. The data of opioid use in ESRD population at the same time is unclear, despite an overall higher prevalence of pain syndromes. In an earlier study of randomly selected patients in 142 DOPPS participating US dialysis units, the fraction of ESRD population prescribed opioids was found to be decreasing, from about 18% in 1997 to 14.9% in 2000, but data on safety were not reported [<xref rid="B9" ref-type="bibr">9</xref>]. In one of the recently published USRDS analysis, Kimmel et al. [<xref rid="B38" ref-type="bibr">38</xref>] demonstrated that approximately 60% of prevalent ESRD patients received at least one prescription for opioids from 2006 to 2010, suggesting that the opioid problem is at least 4-5 folds higher in the ESRD population as compared to general population.</p><p>Considering this burden, our analysis has several unique findings important in highlighting the potential of opioid misuse/overuse in the ESRD population. First, we provide a detailed analysis of the patient characteristics associated with opioid overuse. Specifically, we found that the benzodiazepine use (OR 3.2) has one of the strongest associations with opioid use, whereas those with history of drug dependence (OR 1.3) or smoking (OR 1.3) also suffer from significantly higher opioid use. We additionally found that other conventional socio-medical variables, e.g., race (African Americans), presence of diabetes, peripheral vascular disease or heart disease, and so on, had significant but weaker association (OR 1.03&#8211;1.07) with opioid use. This suggests that although pain is a major problem in our ESRD population, the factors that associate strongly with opioid prescription is not their comorbidities and painful conditions, but history of drug dependence, smoking, and benzodiazepine use. These findings corroborate a single center data of 192 patients where the authors reported nearly 52% of patients on opioid having no documented medical indication for their chronic use [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>Second, our study looks at hospitalizations specifically due to prescription opioid overdose, something that has not been studied before. While Kimmel et al. showed that opioid use is associated with higher overall hospitalization and mortality, our study shows that it increases hospitalization due to prescription opioid overdose, and the odds of this increases by 50%, with concomitant use of benzodiazepines.</p><p>Another significant finding of our study is the trend of opioid use over period of time. In the recently published USRDS analysis, Kimmel et al. indicated a much greater use of opioid (60% vs. 52% of population) compared to our study. However, this discrepancy in the findings is better explained when examining the data with reference to the similar trends in general population, especially a large dip seen in 2011 [<xref rid="B40" ref-type="bibr">40</xref>], attributed to increased awareness of dangers of prescription opioids, introduction of prescription drug monitoring program, and pain clinic regulations. Unfortunately, despite this decrease, we show that the number of hospitalizations in ESRD patients due to opioid overdose continued to rise throughout our study period, likely reflecting a significantly higher burden of comorbidities controlling the outcomes among ESRD patients.</p><p>The biggest aspect of our study is the analysis of safety for the concomitant use of benzodiazepines. While few studies have looked at the use of benzodiazepines in ESRD, no prior study has examined the safety of their concomitant use with opioids [<xref rid="B41" ref-type="bibr">41</xref>]. A study from the Office of Surveillance and Epidemiology, US FDA, in 2016 [<xref rid="B42" ref-type="bibr">42</xref>] demonstrated that the concomitant use of benzodiazepines and opioids in 2014 was around 9.6% in general population, but these rates were 30% in ESRD population in our study. A plausible explanation for this could be the higher prevalence of anxiety and other mental health issues in ESRD patients compared to the general population necessitating the legitimate need for benzodiazepines prescriptions. Our study also shows that the concomitant use of both drugs is associated with a 2.4-fold higher risk of hospitalization with opioid overdose. Simultaneous use of opioids and benzodiazepines has been shown to increase, in a dose-dependent fashion, respiratory depression and risk of death from drug overdose [<xref rid="B43" ref-type="bibr">43</xref>]. In 2016, the FDA issued a black box warning for concomitant use of the two classes of drugs [<xref rid="B44" ref-type="bibr">44</xref>]. It remains to be seen if this black box warning makes a significant difference in the concomitant prescription of both classes of drugs in the ESRD population.</p><p>We also looked at the hospitalization events and analyzed the individual opioids prescribed within 30, 60, or 90 days prior to hospitalization. We found that all opioids were associated with higher odds of hospitalization due to opioid overdose. In addition, the safety profile of the opioid for use in the ESRD population had little relationship with the risk of hospitalization due to an opioid overdose. The opioid with the lowest odds ratio for hospitalization was hydrocodone followed closely by hydromorphone. These two opioids comprised more than half of all opioid prescriptions and are typically classified as &#8220;use with caution&#8221; and &#8220;safe to use,&#8221; respectively. Opioids known to be unsafe for use in ESRD patients and corroborated by individual risk association in this study (such as morphine and meperidine) continue to be prescribed (comprising 2.5% of prescriptions in 2012).</p><p>It was surprising to see that methadone was associated with very high odds of hospitalization, despite being considered a safe drug based on pharmacokinetics. Methadone is a difficult analgesic to manage and needs certain skill sets from the prescribers with appropriate follow-ups to ensure safety of patients. Significant inter- and intra-individual variability in methadone metabolism could explain the discrepancy [<xref rid="B45" ref-type="bibr">45</xref>] with the hospitalization rate. Methadone is also used as part of substance abuse program, and some of these cases of overdose could be on that program, but this data is not readily available and difficult to capture and match with USRDS dataset.</p><p>Opioids to be used with caution, such as oxycodone and oxymorphone, were associated with OR&#8201;&gt;&#8201;3 of hospitalization. Oxycodone was the second most commonly prescribed opioid after hydrocodone. Overall, 40.4% of all opioid prescriptions were written for medications, which were associated with at least a moderate risk (OR of 2 and above) for hospitalization with opioid overdose. In essence, there is no &#8220;safe opioid&#8221; for use in hemodialysis patients, and the nomenclature is misleading. In fact, the WHO analgesic ladder modified for ESRD recommends methadone, fentanyl, oxycodone, and hydromorphone as step 3 for treatment of severe pain [<xref rid="B8" ref-type="bibr">8</xref>]. There are always legitimate reasons for opioid prescriptions, and all opioid prescriptions should not be viewed in the context of misuse. A societal and cultural acceptance of opioids plays a role in the acceptance of opioids for moderate-to-severe pain by both prescribers and the patients alike. The same goes for benzodiazepines too. This highlights the need for education of opioid prescribers regarding safety and selection of individual opioids in ESRD population. There is widespread prevalence of chronic pain, which is not adequately treated; in ESRD patients, opioids should not be withheld for uncontrolled pain for fear of complications. Interestingly, propoxyphene was found to be associated with a lower risk of hospitalization with opioid overdose; however, the association was not significant. It was banned by FDA in 2010 due to significant cardiac toxicity [<xref rid="B46" ref-type="bibr">46</xref>].</p><p>We did not look at prescriber profile or their education, background or competency in this study, but a 2015 study examined the prescription pattern of opioids by specialty. For similar time period (2007&#8211;2012) [<xref rid="B47" ref-type="bibr">47</xref>], it was found that primary care physicians wrote 11.2% and nonphysician providers wrote 44.5% of prescriptions. Hence, education regarding safety of these opioids in the ESRD population, targeting these providers, is paramount. Another limitation of our study is that we included patients only on Medicare (A and B) and part D. It is possible that patients covered by other insurance received opioid prescription not captured by our study.However, considering that the majority of hemodialysis patients have Medicare coverage, this number should be small, and possibly, would lead to an underestimation of opioid use.</p><p>In the current climate of opioid crisis, nonopioid options should always be considered first. Physical therapy and massage therapy may help with improving physical pain and range of motion. Psychotherapy including cognitive behavioral therapy may help with coping skills. There is a plethora of interventional pain procedures for which a referral to an interventional pain medicine expert could be valuable. Acetaminophen and NSAIDs are safe to use with dose adjustment and monitoring for gastrointestinal side effects [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>]. Adjuvants such as antiepileptics, antidepressants, and topical anesthetics can be considered.</p><p>This study demonstrates that the concept of safe, use with caution, and unsafe opioids in ESRD, while meaningful with regard to pharmacokinetics, is less meaningful with regard to resultant hospitalizations for opioid overdose. Concomitant opioid and benzodiazepine prescriptions even for legitimate reasons should be strictly monitored, and continuous prescriber education as well as competency improvement and assessment may play an important role in ensuring patient safety. More well-planned prospective studies involving multiple stake holders, including palliative care experts, will help to validate the findings of our retrospective study as well as suggest a better approach for managing opioids and benzodiazepines in ESRD patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the Gatorade Trust through funds distributed by the University of Florida, Division of Nephrology, Hypertension, and Renal Transplantation. TOB was supported by R01 GM110240 and by Sepsis and Critical Illness Research Center Award P50 GM-111152 from the National Institute of General Medical Sciences and has received grant (97071) from Clinical and Translational Science Institute, University of Florida. Publication of this article was funded in part by the University of Florida Open Access Publishing Fund.</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The USRDS Standard Analysis Files (SAFs) data used to support the findings of this study may be released upon application to the United States Renal Data System (USRDS), who can be contacted at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.usrds.org/request.aspx">https://www.usrds.org/request.aspx</ext-link> or by e-mail to <email>USRDS@usrds.org</email>.</p></sec><sec><title>Disclosure</title><p>The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the U.S. government.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>All authors have no conflicts of interest to declare.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="supp-1" position="float" orientation="portrait"><label>Supplementary Materials</label><caption><p>Table 1S: Updated Classification of opioids for use in ESRD. Table 2S: frequency of opioid prescriptions from 2006 to 2012 according to generic name.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="3865924.f1.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davison</surname><given-names>S. N.</given-names></name></person-group><article-title>Pain in hemodialysis patients: prevalence, cause, severity, and management</article-title><source><italic toggle="yes">American Journal of Kidney Diseases</italic></source><year>2003</year><volume>42</volume><issue>6</issue><fpage>1239</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2003.08.025</pub-id><pub-id pub-id-type="other">2-s2.0-0344395257</pub-id><pub-id pub-id-type="pmid">14655196</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>P. E.</given-names></name></person-group><article-title>Joint problems in patients on maintenance hemodialysis</article-title><source><italic toggle="yes">Clinical Nephrology</italic></source><year>1982</year><volume>18</volume><issue>5</issue><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">7151339</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisbord</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Fried</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R. M.</given-names></name><etal/></person-group><article-title>Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients</article-title><source><italic toggle="yes">Journal of the American Society of Nephrology</italic></source><year>2005</year><volume>16</volume><issue>8</issue><fpage>2487</fpage><lpage>2494</lpage><pub-id pub-id-type="doi">10.1681/asn.2005020157</pub-id><pub-id pub-id-type="other">2-s2.0-28444479454</pub-id><pub-id pub-id-type="pmid">15975996</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fainsinger</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Davison</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Brenneis</surname><given-names>C.</given-names></name></person-group><article-title>A supportive care model for dialysis patients</article-title><source><italic toggle="yes">Palliative Medicine</italic></source><year>2003</year><volume>17</volume><issue>1</issue><fpage>81</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1191/0269216303pm666xx</pub-id><pub-id pub-id-type="other">2-s2.0-0037279018</pub-id><pub-id pub-id-type="pmid">12597471</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davison</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Jhangri</surname><given-names>G. S.</given-names></name></person-group><article-title>The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients</article-title><source><italic toggle="yes">Journal of Pain and Symptom Management</italic></source><year>2005</year><volume>30</volume><issue>5</issue><fpage>465</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2005.05.013</pub-id><pub-id pub-id-type="other">2-s2.0-21544461902</pub-id><pub-id pub-id-type="pmid">16310620</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tohme</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mor</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Pena-Polanco</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Predictors and outcomes of non-adherence in patients receiving maintenance hemodialysis</article-title><source><italic toggle="yes">International Urology and Nephrology</italic></source><year>2017</year><volume>49</volume><issue>8</issue><fpage>1471</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1007/s11255-017-1600-4</pub-id><pub-id pub-id-type="other">2-s2.0-85018305913</pub-id><pub-id pub-id-type="pmid">28455663</pub-id><pub-id pub-id-type="pmcid">PMC5522640</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClellan</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Anson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Birkeli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tuttle</surname><given-names>E.</given-names></name></person-group><article-title>Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease</article-title><source><italic toggle="yes">Journal of Clinical Epidemiology</italic></source><year>1991</year><volume>44</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(91)90204-m</pub-id><pub-id pub-id-type="other">2-s2.0-0026079086</pub-id><pub-id pub-id-type="pmid">1986062</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailie</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Bragg-Gresham</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Young</surname><given-names>E. W.</given-names></name></person-group><article-title>Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription</article-title><source><italic toggle="yes">Kidney International</italic></source><year>2004</year><volume>65</volume><issue>6</issue><fpage>2419</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00658.x</pub-id><pub-id pub-id-type="other">2-s2.0-2442638777</pub-id><pub-id pub-id-type="pmid">15149355</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barakzoy</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>A. H.</given-names></name></person-group><article-title>Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease</article-title><source><italic toggle="yes">Journal of the American Society of Nephrology</italic></source><year>2006</year><volume>17</volume><issue>11</issue><fpage>3198</fpage><lpage>3203</lpage><pub-id pub-id-type="doi">10.1681/asn.2006050477</pub-id><pub-id pub-id-type="other">2-s2.0-33750744796</pub-id><pub-id pub-id-type="pmid">16988057</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Corcoran</surname><given-names>A. M.</given-names></name></person-group><article-title>End-stage renal disease: symptom management and advance care planning</article-title><source><italic toggle="yes">American Family Physician</italic></source><year>2012</year><volume>85</volume><issue>7</issue><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">22534347</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>M.</given-names></name></person-group><article-title>Opioids in renal failure and dialysis patients</article-title><source><italic toggle="yes">Journal of Pain and Symptom Management</italic></source><year>2004</year><volume>28</volume><issue>5</issue><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2004.02.021</pub-id><pub-id pub-id-type="other">2-s2.0-7044245703</pub-id><pub-id pub-id-type="pmid">15504625</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davison</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>P. R.</given-names></name></person-group><article-title>Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients</article-title><source><italic toggle="yes">Journal of Opioid Management</italic></source><year>2008</year><volume>4</volume><issue>6</issue><fpage>335</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.5055/jom.2008.0037</pub-id><pub-id pub-id-type="pmid">19192761</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perlman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Giladi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brecht</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Intradialytic clearance of opioids: methadone versus hydromorphone</article-title><source><italic toggle="yes">Pain</italic></source><year>2013</year><volume>154</volume><issue>12</issue><fpage>2794</fpage><lpage>2800</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.08.015</pub-id><pub-id pub-id-type="other">2-s2.0-84889086848</pub-id><pub-id pub-id-type="pmid">23973378</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercadante</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caligara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sapio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Serretta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lodi</surname><given-names>F.</given-names></name></person-group><article-title>Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure</article-title><source><italic toggle="yes">Journal of Pain and Symptom Management</italic></source><year>1997</year><volume>13</volume><issue>4</issue><fpage>241</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/s0885-3924(97)00076-6</pub-id><pub-id pub-id-type="other">2-s2.0-0030935089</pub-id><pub-id pub-id-type="pmid">9136236</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saraf</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Gordeuk</surname><given-names>V. R.</given-names></name><name name-style="western"><surname>Gowhari</surname><given-names>M.</given-names></name></person-group><article-title>Safety of chronic transdermal fentanyl use in patients receiving hemodialysis</article-title><source><italic toggle="yes">American Journal of Health-System Pharmacy</italic></source><year>2016</year><volume>73</volume><issue>13</issue><fpage>947</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.2146/ajhp150748</pub-id><pub-id pub-id-type="other">2-s2.0-84976407185</pub-id><pub-id pub-id-type="pmid">27325876</pub-id><pub-id pub-id-type="pmcid">PMC5378007</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opdal</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Arnesen</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>L. D.</given-names></name><etal/></person-group><article-title>Effects of hemodialysis on methadone pharmacokinetics and QTc</article-title><source><italic toggle="yes">Clinical Therapeutics</italic></source><year>2015</year><volume>37</volume><issue>7</issue><fpage>1594</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2015.04.009</pub-id><pub-id pub-id-type="other">2-s2.0-84937630309</pub-id><pub-id pub-id-type="pmid">25963997</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreek</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Schecter</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Gutjahr</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>M.</given-names></name></person-group><article-title>Methadone use in patients with chronic renal disease</article-title><source><italic toggle="yes">Drug and Alcohol Dependence</italic></source><year>1980</year><volume>5</volume><issue>3</issue><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/0376-8716(80)90180-5</pub-id><pub-id pub-id-type="other">2-s2.0-0018843738</pub-id><pub-id pub-id-type="pmid">6986247</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osborne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grebenik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Trew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>M.</given-names></name></person-group><article-title>The pharmacokinetics of morphine and morphine glucuronides in kidney failure</article-title><source><italic toggle="yes">Clinical Pharmacology and Therapeutics</italic></source><year>1993</year><volume>54</volume><issue>2</issue><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/clpt.1993.127</pub-id><pub-id pub-id-type="other">2-s2.0-0027248094</pub-id><pub-id pub-id-type="pmid">8354025</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osborne</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Joel</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Slevin</surname><given-names>M. L.</given-names></name></person-group><article-title>Morphine intoxication in renal failure: the role of morphine-6-glucuronide</article-title><source><italic toggle="yes">BMJ</italic></source><year>1986</year><volume>292</volume><issue>6535</issue><fpage>1548</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1136/bmj.292.6535.1548</pub-id><pub-id pub-id-type="other">2-s2.0-0022532772</pub-id><pub-id pub-id-type="pmid">3087512</pub-id><pub-id pub-id-type="pmcid">PMC1340555</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodd</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ripel</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>M&#248;rland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiik-Larsen</surname><given-names>E.</given-names></name></person-group><article-title>Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure</article-title><source><italic toggle="yes">Human &amp; Experimental Toxicology</italic></source><year>1990</year><volume>9</volume><issue>5</issue><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1177/096032719000900509</pub-id><pub-id pub-id-type="other">2-s2.0-0025018215</pub-id><pub-id pub-id-type="pmid">2261246</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angst</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>B&#252;hrer</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#246;tsch</surname><given-names>J.</given-names></name></person-group><article-title>Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action</article-title><source><italic toggle="yes">Anesthesiology</italic></source><year>2000</year><volume>92</volume><issue>5</issue><fpage>1473</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1097/00000542-200005000-00038</pub-id><pub-id pub-id-type="other">2-s2.0-0034060094</pub-id><pub-id pub-id-type="pmid">10781294</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guay</surname><given-names>D. R. P.</given-names></name><name name-style="western"><surname>Awni</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Findlay</surname><given-names>J. W. A.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease</article-title><source><italic toggle="yes">Clinical Pharmacology and Therapeutics</italic></source><year>1988</year><volume>43</volume><issue>1</issue><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/clpt.1988.12</pub-id><pub-id pub-id-type="other">2-s2.0-0023931696</pub-id><pub-id pub-id-type="pmid">3335120</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talbott</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Zelikovic</surname><given-names>I.</given-names></name></person-group><article-title>Respiratory arrest precipitated by codeine in a child with chronic renal failure</article-title><source><italic toggle="yes">Clinical Pediatrics</italic></source><year>1997</year><volume>36</volume><issue>3</issue><fpage>171</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1177/000992289703600308</pub-id><pub-id pub-id-type="other">2-s2.0-0030950106</pub-id><pub-id pub-id-type="pmid">9078419</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>G. L. C.</given-names></name><name name-style="western"><surname>Matzke</surname><given-names>G. R.</given-names></name></person-group><article-title>Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics</article-title><source><italic toggle="yes">Drug Intelligence &amp; Clinical Pharmacy</italic></source><year>1987</year><volume>21</volume><issue>10</issue><fpage>773</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1177/106002808702101001</pub-id><pub-id pub-id-type="other">2-s2.0-0023518537</pub-id><pub-id pub-id-type="pmid">3322755</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szeto</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Inturrisi</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Houde</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheigh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reidenberg</surname><given-names>M. M.</given-names></name></person-group><article-title>Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer</article-title><source><italic toggle="yes">Annals of Internal Medicine</italic></source><year>1977</year><volume>86</volume><issue>6</issue><fpage>738</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-86-6-738</pub-id><pub-id pub-id-type="other">2-s2.0-0017653599</pub-id><pub-id pub-id-type="pmid">869353</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Bersten</surname><given-names>A.</given-names></name></person-group><article-title>Normeperidine toxicity</article-title><source><italic toggle="yes">Anesthesia and Analgesia</italic></source><year>1986</year><volume>65</volume><issue>5</issue><fpage>536</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">3963440</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.-C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S.-T.</given-names></name></person-group><article-title>Clearance of meperidine and its metabolite normeperidine in hemodialysis patients with chronic noncancer pain</article-title><source><italic toggle="yes">Journal of Pain and Symptom Management</italic></source><year>2014</year><volume>47</volume><issue>4</issue><fpage>801</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2013.05.007</pub-id><pub-id pub-id-type="other">2-s2.0-84898807879</pub-id><pub-id pub-id-type="pmid">23870842</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickander</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Emmerson</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>H. R.</given-names></name></person-group><article-title>Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review</article-title><source><italic toggle="yes">Human Toxicology</italic></source><year>1984</year><volume>3</volume><issue>1</issue><fpage>13s</fpage><lpage>36s</lpage><pub-id pub-id-type="doi">10.1177/096032718400300103</pub-id><pub-id pub-id-type="pmid">6090306</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbosa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Acute administration of tramadol and tapentadol at effective analgesic and maximum tolerated doses causes hepato- and nephrotoxic effects in wistar rats</article-title><source><italic toggle="yes">Toxicology</italic></source><year>2017</year><volume>389</volume><fpage>118</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2017.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-85021952522</pub-id><pub-id pub-id-type="pmid">28689766</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vadivelu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mirante</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Patient considerations in the use of tapentadol for moderate to severe pain</article-title><source><italic toggle="yes">Drug, Healthcare and Patient Safety</italic></source><year>2013</year><volume>5</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.2147/dhps.s28829</pub-id><pub-id pub-id-type="other">2-s2.0-84879702284</pub-id><pub-id pub-id-type="pmcid">PMC3704302</pub-id><pub-id pub-id-type="pmid">23861601</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murtagh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>M.-O.</given-names></name><name name-style="western"><surname>Donohoe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>P.</given-names></name><name name-style="western"><surname>Higginson</surname><given-names>I.</given-names></name></person-group><article-title>The use of opioid analgesia in end-stage renal disease patients managed without dialysis</article-title><source><italic toggle="yes">Journal of Pain &amp; Palliative Care Pharmacotherapy</italic></source><year>2007</year><volume>21</volume><issue>2</issue><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1080/j354v21n02_03</pub-id><pub-id pub-id-type="pmid">17844723</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>M. E. F.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>R. M.</given-names></name></person-group><article-title>Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis</article-title><source><italic toggle="yes">Palliative Medicine</italic></source><year>2005</year><volume>19</volume><issue>3</issue><fpage>259</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1191/0269216305pm1004cr</pub-id><pub-id pub-id-type="other">2-s2.0-18744365791</pub-id><pub-id pub-id-type="pmid">15920941</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samolsky Dekel</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Donati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vasarri</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dialyzability of oxycodone and its metabolites in chronic noncancer pain patients with end-stage renal disease</article-title><source><italic toggle="yes">Pain Practice</italic></source><year>2017</year><volume>17</volume><issue>5</issue><fpage>604</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1111/papr.12483</pub-id><pub-id pub-id-type="other">2-s2.0-84984846096</pub-id><pub-id pub-id-type="pmid">27589376</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hand</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Sear</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Uppington</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>McQuay</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R. A.</given-names></name></person-group><article-title>Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites</article-title><source><italic toggle="yes">British Journal of Anaesthesia</italic></source><year>1990</year><volume>64</volume><issue>3</issue><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1093/bja/64.3.276</pub-id><pub-id pub-id-type="other">2-s2.0-0025371716</pub-id><pub-id pub-id-type="pmid">2328175</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Griessinger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sittl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Likar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sch&#252;ttler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koppert</surname><given-names>W.</given-names></name></person-group><article-title>Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine</article-title><source><italic toggle="yes">European Journal of Pain</italic></source><year>2006</year><volume>10</volume><issue>8</issue><fpage>p. 743</fpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2005.12.001</pub-id><pub-id pub-id-type="other">2-s2.0-33745035114</pub-id><pub-id pub-id-type="pmid">16426877</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alcorn</surname><given-names>H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Berg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hines</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hait</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sciascia</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus</article-title><source><italic toggle="yes">BMC Nephrology</italic></source><year>2015</year><volume>16</volume><fpage>p. 47</fpage><pub-id pub-id-type="doi">10.1186/s12882-015-0043-3</pub-id><pub-id pub-id-type="other">2-s2.0-84927714798</pub-id><pub-id pub-id-type="pmcid">PMC4392787</pub-id><pub-id pub-id-type="pmid">25885112</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="book"><collab>Centers for Disease Control and Prevention</collab><source><italic toggle="yes">Annual Surveillance Report of Drug-Related Risks and Outcomes</italic></source><year>2017</year><publisher-loc>Atlanta, GA, USA</publisher-loc><publisher-name>Centers for Disease Control and Prevention</publisher-name><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf">https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf</ext-link></comment></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimmel</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Fwu</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Eggers</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Eggers</surname><given-names>P. W.</given-names></name></person-group><article-title>Opioid prescription, morbidity, and mortality in United States dialysis patients</article-title><source><italic toggle="yes">Journal of the American Society of Nephrology</italic></source><year>2017</year><volume>28</volume><issue>12</issue><fpage>3658</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1681/asn.2017010098</pub-id><pub-id pub-id-type="other">2-s2.0-85038432634</pub-id><pub-id pub-id-type="pmid">28935654</pub-id><pub-id pub-id-type="pmcid">PMC5698071</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivo</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S.</given-names></name></person-group><article-title>Opioid use in hemodialysis patients</article-title><source><italic toggle="yes">American Journal of Kidney Diseases</italic></source><year>2015</year><volume>66</volume><issue>6</issue><fpage>1103</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2015.07.029</pub-id><pub-id pub-id-type="other">2-s2.0-84947926972</pub-id><pub-id pub-id-type="pmid">26421755</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>G. P.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Vital signs: changes in opioid prescribing in the United States, 2006&#8211;2015</article-title><source><italic toggle="yes">MMWR. Morbidity and Mortality Weekly Report</italic></source><year>2017</year><volume>66</volume><issue>26</issue><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6626a4</pub-id><pub-id pub-id-type="other">2-s2.0-85024105633</pub-id><pub-id pub-id-type="pmid">28683056</pub-id><pub-id pub-id-type="pmcid">PMC5726238</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cuerden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Suri</surname><given-names>R. S.</given-names></name></person-group><article-title>Opioid and benzodiazepine use in end-stage renal disease: a systematic review</article-title><source><italic toggle="yes">Clinical Journal of the American Society of Nephrology</italic></source><year>2011</year><volume>6</volume><issue>2</issue><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.2215/cjn.04770610</pub-id><pub-id pub-id-type="other">2-s2.0-79951882084</pub-id><pub-id pub-id-type="pmid">21071517</pub-id><pub-id pub-id-type="pmcid">PMC3052223</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Kornegay</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Staffa</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>McAninch</surname><given-names>J. K.</given-names></name></person-group><article-title>Trends in the concomitant prescribing of opioids and benzodiazepines, 2002&#8722;2014</article-title><source><italic toggle="yes">American Journal of Preventive Medicine</italic></source><year>2016</year><volume>51</volume><issue>2</issue><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2016.02.014</pub-id><pub-id pub-id-type="other">2-s2.0-84962802478</pub-id><pub-id pub-id-type="pmid">27079639</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Saitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ganoczy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ilgen</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A. S. B.</given-names></name></person-group><article-title>Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study</article-title><source><italic toggle="yes">BMJ</italic></source><year>2015</year><volume>350</volume><fpage>p. h2698</fpage><pub-id pub-id-type="doi">10.1136/bmj.h2698</pub-id><pub-id pub-id-type="other">2-s2.0-84936797899</pub-id><pub-id pub-id-type="pmid">26063215</pub-id><pub-id pub-id-type="pmcid">PMC4462713</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="book"><collab>US Food &amp; Drug Administration</collab><source><italic toggle="yes">FDA News Release</italic></source><year>2016</year><publisher-loc>Montgomery, MD, USA</publisher-loc><publisher-name>US Food &amp; Drug Administration</publisher-name><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm</ext-link></comment></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friedel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>E. D.</given-names></name></person-group><article-title>Differences in methadone metabolism by CYP2B6 variants</article-title><source><italic toggle="yes">Drug Metabolism and Disposition</italic></source><year>2015</year><volume>43</volume><issue>7</issue><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1124/dmd.115.064352</pub-id><pub-id pub-id-type="other">2-s2.0-84940426119</pub-id><pub-id pub-id-type="pmid">25897175</pub-id><pub-id pub-id-type="pmcid">PMC4468442</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="book"><collab>US Food &amp; Drug Administration</collab><source><italic toggle="yes">FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Propoxyphene</italic></source><year>2010</year><publisher-loc>Montgomery, MD, USA</publisher-loc><publisher-name>US Food &amp; Drug Administration</publisher-name><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/Drugs/DrugSafety/ucm234338.htm">https://www.fda.gov/Drugs/DrugSafety/ucm234338.htm</ext-link></comment></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paulozzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C. M.</given-names></name></person-group><article-title>Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007&#8211;2012</article-title><source><italic toggle="yes">American Journal of Preventive Medicine</italic></source><year>2015</year><volume>49</volume><issue>3</issue><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2015.02.020</pub-id><pub-id pub-id-type="other">2-s2.0-84941414657</pub-id><pub-id pub-id-type="pmid">25896191</pub-id><pub-id pub-id-type="pmcid">PMC6034509</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescott</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Speirs</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Critchley</surname><given-names>J. A. J. H.</given-names></name><name name-style="western"><surname>Temple</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Winney</surname><given-names>R. J.</given-names></name></person-group><article-title>Paracetamol disposition and metabolite kinetics in patients with chronic renal failure</article-title><source><italic toggle="yes">European Journal of Clinical Pharmacology</italic></source><year>1989</year><volume>36</volume><issue>3</issue><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1007/bf00558162</pub-id><pub-id pub-id-type="other">2-s2.0-0024592806</pub-id><pub-id pub-id-type="pmid">2744070</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Weisbord</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Germain</surname><given-names>M. J.</given-names></name></person-group><article-title>Renal palliative care</article-title><source><italic toggle="yes">Journal of Palliative Medicine</italic></source><year>2006</year><volume>9</volume><issue>4</issue><fpage>977</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1089/jpm.2006.9.977</pub-id><pub-id pub-id-type="other">2-s2.0-33747876890</pub-id><pub-id pub-id-type="pmid">16910813</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>A schematic diagram of patient selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="PRM2019-3865924.001.jpg"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Figures describing the trend of opioid prescription use (a) and class of prescribed opioid from 2006&#8211;2012 (b).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="PRM2019-3865924.002.jpg"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical characteristics of study cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">All patients</th><th align="center" rowspan="1" colspan="1">Patients without opioid prescription</th><th align="center" rowspan="1" colspan="1">Patients with at least one opioid prescription</th><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">p</italic> value</th><th rowspan="1" colspan="1"/></tr><tr><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;643,859</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;163,399</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#8201;=&#8201;480,460</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> missing</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean&#8201;&#177;&#8201;SD</td><td align="center" rowspan="1" colspan="1">62&#8201;&#177;&#8201;15</td><td align="center" rowspan="1" colspan="1">65&#8201;&#177;&#8201;15</td><td align="center" rowspan="1" colspan="1">61&#8201;&#177;&#8201;15</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender, female <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">302,489 (47)</td><td align="center" rowspan="1" colspan="1">67,758 (42)</td><td align="center" rowspan="1" colspan="1">234,731 (49)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">74</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, black, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">223,264 (35)</td><td align="center" rowspan="1" colspan="1">52,997 (32)</td><td align="center" rowspan="1" colspan="1">170,267 (35)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, mean&#8201;&#177;&#8201;SD</td><td align="center" rowspan="1" colspan="1">29&#8201;&#177;&#8201;8</td><td align="center" rowspan="1" colspan="1">28&#8201;&#177;&#8201;8</td><td align="center" rowspan="1" colspan="1">29&#8201;&#177;&#8201;8</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Primary cause of ESRD, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes</td><td align="center" rowspan="1" colspan="1">304,753 (47)</td><td align="center" rowspan="1" colspan="1">75,446 (46)</td><td align="center" rowspan="1" colspan="1">229,307 (48)</td><td rowspan="6" align="center" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension</td><td align="center" rowspan="1" colspan="1">185,800 (29)</td><td align="center" rowspan="1" colspan="1">49,757 (30)</td><td align="center" rowspan="1" colspan="1">136,043 (28)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Glomerulonephritis</td><td align="center" rowspan="1" colspan="1">63,178 (10)</td><td align="center" rowspan="1" colspan="1">14,381 (9)</td><td align="center" rowspan="1" colspan="1">48,797 (10)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cystic kidney</td><td align="center" rowspan="1" colspan="1">12,592 (2)</td><td align="center" rowspan="1" colspan="1">3,068 (2)</td><td align="center" rowspan="1" colspan="1">9,524 (2)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Urologic disorders</td><td align="center" rowspan="1" colspan="1">8,543 (1)</td><td align="center" rowspan="1" colspan="1">2,219 (1)</td><td align="center" rowspan="1" colspan="1">6,324 (1)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Others</td><td align="center" rowspan="1" colspan="1">45,403 (7)</td><td align="center" rowspan="1" colspan="1">11,522 (7)</td><td align="center" rowspan="1" colspan="1">33,881 (7)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Comorbidity, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension</td><td align="center" rowspan="1" colspan="1">543410 (86.2)</td><td align="center" rowspan="1" colspan="1">136,963 (85.6)</td><td align="center" rowspan="1" colspan="1">406,447 (86.4)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,267</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes</td><td align="center" rowspan="1" colspan="1">351,024 (54.9)</td><td align="center" rowspan="1" colspan="1">86,932 (53.8)</td><td align="center" rowspan="1" colspan="1">264,092 (55.3)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4,474</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Atherosclerotic heart disease</td><td align="center" rowspan="1" colspan="1">127,296 (19.9)</td><td align="center" rowspan="1" colspan="1">34,025 (21.0)</td><td align="center" rowspan="1" colspan="1">93,271 (19.5)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">4,488</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Chronic heart failure</td><td align="center" rowspan="1" colspan="1">197,713 (31.4)</td><td align="center" rowspan="1" colspan="1">50,826 (31.8)</td><td align="center" rowspan="1" colspan="1">146,887 (31.2)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,276</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cerebrovascular disease</td><td align="center" rowspan="1" colspan="1">58,006 (9.2)</td><td align="center" rowspan="1" colspan="1">15,500 (9.7)</td><td align="center" rowspan="1" colspan="1">42,506 (9.0)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,267</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Peripheral vascular disease</td><td align="center" rowspan="1" colspan="1">82,008 (13.0)</td><td align="center" rowspan="1" colspan="1">20,671 (12.9)</td><td align="center" rowspan="1" colspan="1">61,337 (13.0)</td><td align="center" rowspan="1" colspan="1">0.261</td><td align="center" rowspan="1" colspan="1">13,277</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Drug dependence</td><td align="center" rowspan="1" colspan="1">8,540 (1.4)</td><td align="center" rowspan="1" colspan="1">1,442 (0.9)</td><td align="center" rowspan="1" colspan="1">7,098 (1.5)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,277</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Alcohol dependence</td><td align="center" rowspan="1" colspan="1">9,213 (1.5)</td><td align="center" rowspan="1" colspan="1">2,186 (1.4)</td><td align="center" rowspan="1" colspan="1">7,027 (1.5)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,277</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Smoking</td><td align="center" rowspan="1" colspan="1">40,384 (6.4)</td><td align="center" rowspan="1" colspan="1">7,692 (4.8)</td><td align="center" rowspan="1" colspan="1">32,692 (6.9)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">13,277</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Medication use, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Benzodiazepine</td><td align="center" rowspan="1" colspan="1">162,713 (25.3)</td><td align="center" rowspan="1" colspan="1">18,529 (11.3)</td><td align="center" rowspan="1" colspan="1">144,184 (30.0)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Association between clinical characteristics and having at least one opioid.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">&#8201;</th><th align="center" rowspan="2" colspan="1">Referent</th><th align="center" colspan="2" rowspan="1">Unadjusted</th><th align="center" colspan="2" rowspan="1">Multivariable logistic regression</th></tr><tr><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.983 (0.983&#8211;0.984)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">0.984 (0.983&#8211;0.984)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1.352 (1.336&#8211;1.367)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.419 (1.402&#8211;1.436)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Race</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;African Americans</td><td align="center" rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">1.093 (1.080&#8211;1.107)</td><td rowspan="5" align="center" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.030 (1.017&#8211;1.044)</td><td rowspan="5" align="center" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Asian</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.602 (0.587&#8211;0.618)</td><td align="center" rowspan="1" colspan="1">0.626 (0.610&#8211;0.643)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Native Americans</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.969 (0.919&#8211;1.020)</td><td align="center" rowspan="1" colspan="1">0.918 (0.870&#8211;0.969)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Others</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.529 (0.485&#8211;0.578)</td><td align="center" rowspan="1" colspan="1">0.494 (0.452&#8211;0.541)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.537 (0.302&#8211;0.954)</td><td align="center" rowspan="1" colspan="1">0.402 (0.220&#8211;0.734)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" colspan="6" rowspan="1">Primary disease ESRD</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes</td><td align="center" rowspan="1" colspan="1">Other causes</td><td align="center" rowspan="1" colspan="1">1.070 (1.058&#8211;1.083)</td><td rowspan="3" align="center" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.037 (1.021&#8211;1.054)</td><td rowspan="3" align="center" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cystic kidney</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.089 (1.044&#8211;1.136)</td><td align="center" rowspan="1" colspan="1">0.990 (0.948&#8211;1.035)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Urologic disorders</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.004 (0.955&#8211;1.055)</td><td align="center" rowspan="1" colspan="1">1.079 (1.025&#8211;1.136)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;BMI</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.021 (1.021&#8211;1.022)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Hypertension</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.063 (1.046&#8211;1.080)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.052 (1.035&#8211;1.070)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Diabetes</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.074 (1.062&#8211;1.086)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.074 (1.057&#8211;1.092)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Atherosclerotic heart disease</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.915 (0.902&#8211;0.928)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Chronic heart failure</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.974 (0.962&#8211;0.986)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.032 (1.018&#8211;1.045)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Cerebrovascular disease</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">0.925 (0.907&#8211;0.943)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">0.972 (0.952&#8211;0.992)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Peripheral vascular disease</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.010 (0.993&#8211;1.027)</td><td align="center" rowspan="1" colspan="1">0.261</td><td align="center" rowspan="1" colspan="1">1.064 (1.045&#8211;1.083)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Drug dependence</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.681 (1.588&#8211;1.780)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.309 (1.232&#8211;1.390)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Alcohol dependence</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.094 (1.042&#8211;1.148)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">0.940 (0.893&#8211;0.990)</td><td align="center" rowspan="1" colspan="1">0.019</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Smoking</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">1.477 (1.440&#8211;1.516)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">1.321 (1.286&#8211;1.357)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Benzodiazepine</td><td align="left" rowspan="1" colspan="1">&#8201;</td><td align="center" rowspan="1" colspan="1">3.334 (3.279&#8211;3.390)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td><td align="center" rowspan="1" colspan="1">3.271 (3.216&#8211;3.326)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Frequencies of adverse events according to opioid prescription use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">&#8201;</th><th align="center" rowspan="1" colspan="1">All <italic toggle="yes">N</italic> (%)</th><th align="center" rowspan="1" colspan="1">Patients without opioid prescription <italic toggle="yes">N</italic> (%)</th><th align="center" rowspan="1" colspan="1">Patients with at least one opioid prescription <italic toggle="yes">N</italic> (%)</th><th align="center" rowspan="2" colspan="1">
<italic toggle="yes">p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;643,859)</th><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;163,399)</th><th align="center" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#8201;=&#8201;480,460)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients with at least one hospital admission with a diagnosis of opioid overdose, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">3,370 (0.52)</td><td align="center" rowspan="1" colspan="1">139 (0.09)</td><td align="center" rowspan="1" colspan="1">3,231 (0.67)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Death due to drug overdose, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">155 (0.02)</td><td align="center" rowspan="1" colspan="1">18 (0.01)</td><td align="center" rowspan="1" colspan="1">137 (0.03)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Death due to opioid overdose (definition: death due to drug overdose during hospitalization with a diagnosis of opioid overdose), <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">6 (0.00)</td><td align="center" rowspan="1" colspan="1">1 (0.00)</td><td align="center" rowspan="1" colspan="1">5 (0.00)</td><td align="center" rowspan="1" colspan="1">0.624</td></tr><tr><td align="left" rowspan="1" colspan="1">Total LOS, median (IQR)</td><td align="center" rowspan="1" colspan="1">28 (12&#8211;59)</td><td align="center" rowspan="1" colspan="1">22 (9&#8211;48)</td><td align="center" rowspan="1" colspan="1">31 (13&#8211;62)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total ICU LOS, median (IQR)</td><td align="center" rowspan="1" colspan="1">6 (2&#8211;16)</td><td align="center" rowspan="1" colspan="1">5 (1&#8211;14)</td><td align="center" rowspan="1" colspan="1">6 (2&#8211;16)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LOS in patients with opioid overdose, median (IQR)</td><td align="center" rowspan="1" colspan="1">4 (2&#8211;8)</td><td align="center" rowspan="1" colspan="1">5 (3&#8211;10)</td><td align="center" rowspan="1" colspan="1">4 (2&#8211;8)</td><td align="center" rowspan="1" colspan="1">0.326</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU LOS in patients with opioid overdose, median (IQR)</td><td align="center" rowspan="1" colspan="1">2 (1&#8211;4)</td><td align="center" rowspan="1" colspan="1">2 (1&#8211;5)</td><td align="center" rowspan="1" colspan="1">2 (1&#8211;4)</td><td align="center" rowspan="1" colspan="1">0.144</td></tr><tr><td align="left" rowspan="1" colspan="1">Annual Medicare cost per patient ($1000), median (IQR)</td><td align="center" rowspan="1" colspan="1">43 (23&#8211;70)</td><td align="center" rowspan="1" colspan="1">33 (14&#8211;57)</td><td align="center" rowspan="1" colspan="1">46 (26&#8211;73)</td><td align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>IQR, interquartile range; ICU, intensive care unit; LOS, length of stay.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Proposed classification of opioids based on risk for hospitalization due to opioid overdose in ESRD patients on hemodialysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Original classification</th><th align="center" rowspan="2" colspan="1">Drug</th><th align="center" rowspan="1" colspan="1">Hospitalization within 30 days</th><th align="center" rowspan="1" colspan="1">Hospitalization within 60 days</th><th align="center" rowspan="1" colspan="1">Hospitalization within 90 days</th><th align="center" rowspan="2" colspan="1">Proposed classification<sup>^</sup></th></tr><tr><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Safe</td><td align="center" rowspan="1" colspan="1">Hydromorphone</td><td align="center" rowspan="1" colspan="1">2.5 (2.2&#8211;2.8)</td><td align="center" rowspan="1" colspan="1">1.9 (1.7&#8211;2.1)</td><td align="center" rowspan="1" colspan="1">1.7 (1.5&#8211;1.9)</td><td align="center" rowspan="1" colspan="1">Moderate risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Fentanyl</td><td align="center" rowspan="1" colspan="1">3.0 (2.7&#8211;3.6)</td><td align="center" rowspan="1" colspan="1">2.8 (2.5&#8211;3.1)</td><td align="center" rowspan="1" colspan="1">2.7 (2.4&#8211;3.0)</td><td align="center" rowspan="1" colspan="1">High risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Methadone</td><td align="center" rowspan="1" colspan="1">6.0 (5.2&#8211;6.9)</td><td align="center" rowspan="1" colspan="1">5.3 (4.7&#8211;6.1)</td><td align="center" rowspan="1" colspan="1">4.8 (4.2&#8211;5.4)</td><td align="center" rowspan="1" colspan="1">Very high risk</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Caution</td><td align="center" rowspan="1" colspan="1">Buprenorphine</td><td align="center" rowspan="1" colspan="1">5.4 (2.7&#8211;10.5)</td><td align="center" rowspan="1" colspan="1">3.9 (2.1&#8211;7.2)</td><td align="center" rowspan="1" colspan="1">4.3 (2.5&#8211;7.2)</td><td align="center" rowspan="1" colspan="1">Very high risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Hydrocodone</td><td align="center" rowspan="1" colspan="1">1.9 (1.8&#8211;2.0)</td><td align="center" rowspan="1" colspan="1">1.7 (1.6&#8211;1.8)</td><td align="center" rowspan="1" colspan="1">1.7 (1.6&#8211;1.8)</td><td align="center" rowspan="1" colspan="1">Low risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Oxycodone</td><td align="center" rowspan="1" colspan="1">3.1 (2.9&#8211;3.3)</td><td align="center" rowspan="1" colspan="1">2.7 (2.6&#8211;2.9)</td><td align="center" rowspan="1" colspan="1">2.6 (2.4&#8211;2.7)</td><td align="center" rowspan="1" colspan="1">High risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Oxymorphone</td><td align="center" rowspan="1" colspan="1">4.6 (3.0&#8211;7.1)</td><td align="center" rowspan="1" colspan="1">4.3 (2.9&#8211;6.2)</td><td align="center" rowspan="1" colspan="1">3.4 (2.4&#8211;4.9)</td><td align="center" rowspan="1" colspan="1">Very high risk</td></tr><tr><td align="left" colspan="6" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="6" colspan="1">Unsafe</td><td align="center" rowspan="1" colspan="1">Meperidine</td><td align="center" rowspan="1" colspan="1">3.5 (1.7&#8211;7.1)</td><td align="center" rowspan="1" colspan="1">2.6 (1.4&#8211;4.9)</td><td align="center" rowspan="1" colspan="1">2.6 (1.5&#8211;4.6)</td><td align="center" rowspan="1" colspan="1">High risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Morphine</td><td align="center" rowspan="1" colspan="1">6.9 (6.2&#8211;7.6)</td><td align="center" rowspan="1" colspan="1">5.8 (5.2&#8211;6.4)</td><td align="center" rowspan="1" colspan="1">5.2 (4.7&#8211;5.7)</td><td align="center" rowspan="1" colspan="1">Very high risk</td></tr><tr><td align="center" rowspan="1" colspan="1">Codeine</td><td align="center" rowspan="1" colspan="1">2.0 (0.8&#8211;4.8)</td><td align="center" rowspan="1" colspan="1">2.0 (1.0&#8211;4.3)</td><td align="center" rowspan="1" colspan="1">1.8 (0.9&#8211;3.6)</td><td align="center" rowspan="1" colspan="1">N/A<sup><italic toggle="yes">&#8727;</italic></sup></td></tr><tr><td align="center" rowspan="1" colspan="1">Tapentadol</td><td align="center" rowspan="1" colspan="1">1.8 (0.2&#8211;12.8)</td><td align="center" rowspan="1" colspan="1">1.7 (0.4&#8211;6.9)</td><td align="center" rowspan="1" colspan="1">2.0 (0.6&#8211;6.3)</td><td align="center" rowspan="1" colspan="1">N/A<sup><italic toggle="yes">&#8727;&#8727;</italic></sup></td></tr><tr><td align="center" rowspan="1" colspan="1">Propoxyphene</td><td align="center" rowspan="1" colspan="1">0.8 (0.6&#8211;1.0)</td><td align="center" rowspan="1" colspan="1">0.8 (0.6&#8211;0.9)</td><td align="center" rowspan="1" colspan="1">0.7 (0.6&#8211;0.9)</td><td align="center" rowspan="1" colspan="1">N/A<sup><italic toggle="yes">&#8727;&#8727;&#8727;</italic></sup></td></tr><tr><td align="center" rowspan="1" colspan="1">Benzodiazepine</td><td align="center" rowspan="1" colspan="1">1.5 (1.4&#8211;1.7)</td><td align="center" rowspan="1" colspan="1">1.5 (1.4&#8211;1.7)</td><td align="center" rowspan="1" colspan="1">1.5 (1.4&#8211;1.6)</td><td align="left" rowspan="1" colspan="1">&#8201;</td></tr></tbody></table><table-wrap-foot><fn><p>OR, odds ratio of hospitalization due to opioid overdose; CI, confidence interval. Multivariable logistic regression models included all opioids and benzodiazepines. <sup>^</sup>Based on risk stratification using OR at 30 days: low risk, OR 1&#8211;1.9; moderate risk, OR 2&#8211;2.9; high risk, OR 3&#8211;3.9; very high risk, OR 4 and above. <sup><italic toggle="yes">&#8727;</italic></sup>Not statistically significant, <sup><italic toggle="yes">&#8727;&#8727;</italic></sup>not statistically significant and wide CI due to sparse data, and <sup><italic toggle="yes">&#8727;&#8727;&#8727;</italic></sup>drug no longer available in market.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>